These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31404304)

  • 41. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
    Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.
    El Missiry M; Hjorth-Hansen H; Richter J; Olson-Strömberg U; Stenke L; Porkka K; Kreutzman A; Mustjoki S
    PLoS One; 2017; 12(1):e0171041. PubMed ID: 28135325
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New Developments in Chronic Myeloid Leukemia: Implications for Therapy.
    Tabarestani S; Movafagh A
    Iran J Cancer Prev; 2016 Feb; 9(1):e3961. PubMed ID: 27366312
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chronic Myeloid Leukemia with an e6a2
    Crampe M; Haslam K; Groarke E; Kelleher E; O'Shea D; Conneally E; Langabeer SE
    Case Rep Hematol; 2017; 2017():9071702. PubMed ID: 29123930
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Diagnosis and evaluation of the response to treatment of chronic myeloid leukaemia in Mali by fluorescent in situ hybridization].
    Sidibé CO; Samassékou O; Bathily M; Ly M; Diallo Y; Landouré G; Traoré SF; Guinto CO; Traoré M
    Health Sci Dis; 2022 Jul; 23(7):6-9. PubMed ID: 39239208
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.
    Shi XB; Jiang JF; Jin FX; Cheng W
    World J Clin Cases; 2019 May; 7(9):1087-1092. PubMed ID: 31123683
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chronic myeloid leukemia: cytogenetic methods and applications for diagnosis and treatment.
    Morris CM
    Methods Mol Biol; 2011; 730():33-61. PubMed ID: 21431633
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Chronic Myelogenous Leukemia (CML) Case with a Cryptic Insertion of the ABL1 Gene of Chromosome 9 into 22 Resulting in a Fusion Signal on the Derivative 22: 46,XY.ish ins(22;9)(q11.2;q34q34)BCR+,ABL1.
    Boles J; DeNicola M; Collins R; Garcia R; Patel S; Satayasoontorn K; Tirado CA
    J Assoc Genet Technol; 2013; 39(1):21-2. PubMed ID: 26030620
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
    Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
    PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A rare e14a3 BCR/ABL fusion transcript in acute lymphoblastic leukemia patient treated with CAR-modified T-cell therapy.
    Cai H; Yang L; Shen K; Zhang W; Xiong J; Zhang M; Mao X; Wang Y; Xiao M
    Oncol Lett; 2018 Feb; 15(2):2491-2494. PubMed ID: 29434963
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript.
    Swaminathan M; Patel KP; Huynh-Lu J; Tang G; Zuo Z; Miranda R; Verstovsek S
    Acta Haematol; 2019; 141(1):23-27. PubMed ID: 30463063
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.
    García-Gutiérrez V; Gómez-Casares MT; Puerta JM; Alonso-Domínguez JM; Osorio S; Hernández-Boluda JC; Collado R; Ramírez MJ; Ibáñez F; Martín ML; Rodríguez-Gambarte JD; Martínez-Laperche C; Gómez M; Fiallo DV; Redondo S; Rodríguez A; Ruiz-Nuño C; Steegmann JL; Jiménez-Velasco A;
    PLoS One; 2017; 12(3):e0173532. PubMed ID: 28278193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
    Rostami G; Hamid M; Jalaeikhoo H
    Gene; 2017 Sep; 627():202-206. PubMed ID: 28627443
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia.
    Vasconcelos AP; Azevedo IF; Melo FCBC; Neves WB; Azevedo ACAC; Melo RAM
    Genet Mol Res; 2017 Apr; 16(2):. PubMed ID: 28437552
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9.
    Sindt A; Deau B; Brahim W; Staal A; Visanica S; Villarese P; Rault JP; Macintyre E; Delabesse E
    Genes Chromosomes Cancer; 2006 Jun; 45(6):575-82. PubMed ID: 16518848
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
    Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
    Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BCR-ABL1 transcript decline ratio combined BCR-ABL1
    Cai Z; Jia X; Zi J; Song H; Wang S; McGrath M; Zhao L; Song C; Ge Z
    J Cancer; 2020; 11(8):2234-2240. PubMed ID: 32127950
    [No Abstract]   [Full Text] [Related]  

  • 58. Evaluation of a novel multiplex RT-qPCR assay for the quantification of leukemia-associated BCR-ABL1 translocation.
    Kottwitz D; El Hadi H; El Amrani M; Cabezas S; Dehbi H; Nadifi S; Quessar A; Colomer D; Moumen A; Sefrioui EL
    Int J Hematol; 2015 Sep; 102(3):335-41. PubMed ID: 26243622
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Unusual location of BCR-ABL1 fusion sequences in a chronic myeloid leukemia patient.
    Zámečníkova A; Al Bahar S; Pandita R
    Hematology; 2012 Nov; 17(6):321-4. PubMed ID: 22989955
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Variant e19a2 BCR-ABL1 fusion transcript in typical chronic myeloid leukemia.
    Tutulan-Cunita AC; Chirieac SM; Mocanu G; Luca C; Costache M; Lungeanu A; Arghir A
    Clin Lab; 2011; 57(9-10):785-8. PubMed ID: 22029197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.